BAKU, Azerbaijan, Feb.24
Iran has the potential to obtain $40 million in revenues from pharmaceutical export, said a CEO of an active knowledge-based accelerator in the field of biotechnology Hooman Kaghazian, Trend reports citing IRNA.
"Two Iranian accelerators have unveiled five antibiotic products on Tuesday and these pharmaceutical products have the potential to bring in $40 million in revenues," said Kaghazian.
"Accelerators have created major biotechnology platforms for recombinants, animal based, bacterial, yeast, and non-recombinant biological products that include vaccine for livestock and humans, stem cells," he said.
"Knowledge-based companies have unveiled new generation of antibiotics that have biological origin. Omiganan is one of the products that is antimicrobial peptide for infections and our product is manufactured for treating diabetic foot ulcer," he said.
"Another producti is Telavancin that is bactericidal lipoglycopeptide for use in MRSA or other Gram-positive infections," Kaghazian said.